KU Leuven and FIT Biotech Enter Into a Worldwide License Agreement
News Jul 30, 2013
KU Leuven and FIT Biotech have announced that they entered into a worldwide license and collaboration agreement for the development of novel immunotherapeutics based on FIT Biotech's proprietary Gene Transport Unit (GTU) technology for transient in vivo expression of monoclonal antibodies.
The agreement provides KU Leuven with an exclusive worldwide license to six undisclosed proprietary antibodies or marketed recombinant products.
“FIT Biotech continues to apply its platform technology in several therapeutic areas through collaborations and its own research and business development,” said Kalevi Reijonen, CEO and President, FIT Biotech Ltd.
Reijonen continued, “This agreement reflects our strategy to maximize the value of our technology by partnering with companies or universities that have a unique expertise to drive the development of promising vaccines or immunotherapeutics.”
“We are extremely delighted to collaborate with FIT Biotech and build further on their powerful technology platform,” said Nick Geukens, Research Manager of PharmAbs, the KU Leuven antibody center.
Geukens continued, “Our R&D program meets the clear need for more selective and effective management strategies to combat nosocomial infections and cancer. By commercializing our R&D programs we ultimately aim to establish a new, fully-dedicated Flemish spin-off company that will be responsible for (pre)clinical development and marketing of the generated products.”
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018